Powered by

New U.S. patent related to Oasmia Pharmaceutical's nanotechnology platform XR17 has been granted

Nov 20, 2018 - Thomson Reuters ONE

Oasmia Pharmaceutical AB (Nasdaq: OASM) announces that the United States Patent and Trademark Office (USPTO) has issued a notification of allowance of a patent for its unique nanotech method to produce novel pharmaceutical formulations. The patent will be published on November 27th, 2018.

The patent covers the method to characterize Oasmia's patented excipient XR17, that delivers human and animal cancer drugs less invasive and more effectively. Thus, the patented method is an advantageous ...